PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

pharmaphorum

JUNE 2, 2021

As is often the case, the initial guidance will form the basis for negotiations with Roche on the price of the drug, in the hope that an agreement can be reached that will provide access to the medicine by NHS England. Comments can be submitted until 23 June. — Spinal Muscular Atrophy UK (@SMA_UK_) June 2, 2021.

Documentation 52

Documentation Communication 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

European Pharmaceutical Review

JULY 11, 2022

Dr Jack Tan, Senior Postdoctoral Scientist at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, added: ?“We is designed to focus the immune response on parts of RBD shared by all viruses in the Severe Acute Respiratory Syndrome (SARS)-like Betacoronavirus family. 2 is the virus that causes COVID-19.).

Vaccines 91

Vaccines Immunization 91